YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as co…
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew…
Immuneering Corporation - Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corpor…
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a…
Shares of Immuneering Corporation IMRX were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with mod…
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in…
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related adverse events occurring i…
(RTTNews) - Friday's Top Gainers included Replimune, which is preparing to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma; Clearmind Medicine, which strengthened its global intellectual property portfolio thr…
(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Thursday announced encouraging initial data from the Phase 2a trial for Atebimetinib in combination with mGnP for treating metastatic pancreatic cancer.…
(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Monday presented promising genetic data from clinical trials of cancer drug Atebimetinib at the annual meeting of the American Association of Cancer Res…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive…
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one o…
Quick Read X4 Pharmaceuticals (XFOR) at $3.97, target $12, raised $240.3M; Immuneering (IMRX) at $5.48, target $12; Tango Therapeutics (TNGX) at $16.60, target $24, up 87.25% YTD, 43.89% past week. X4 Pharmaceuticals, Immuneering, and Tang…
(RTTNews) - Immuneering Corp. (IMRX) announced positive updated results from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer. Despite the…
(RTTNews) - Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine / nab-paclitaxel (mGnP) in first-line…
(RTTNews) - Immuneering Corp. (IMRX), a late-stage clinical oncology company, announced that it is on track to dose the first patient in its planned phase 3 trial of Atebimetinib in first-line metastatic pancreatic cancer patients in mid-2…
Immuneering Corporation NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is…
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment pa…
Immuneering Corporation - Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with…
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway…
The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies. Many pharma giants, like Amgen, Novo Nordisk and Pfizer, reported ea…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Apple (AAPL) to Hold fr…
[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader [https://seekingalpha.com/author/…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Tuesday, Immuneering's Director, Peter Fei…
Immuneering Corporation (NASDAQ:IMRX) is among the best fast money stocks to buy now. Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 a…
[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures ticked higher in the premarket hours of Thursday as investors awaited the release of key jobs data, hoping for signals on labor market st…
(RTTNews) - Several biotech stocks hit new highs during regular trading on Wednesday, with some extending their gains in after-hours trading. While positive trial results in myotonic dystrophy type 1 lifted PepGen in after-hours trading, a…
Immuneering Corporation NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public…
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914…
* Immuneering (NASDAQ:IMRX [https://seekingalpha.com/symbol/IMRX]) has launched a proposed underwritten public offering of Class A common stock or pre-funded warrants. * The company may grant underwriters a 30-day option to purchase up to…
Immuneering Corporation NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offerin…
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class…
- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial…
Immuneering Corporation Thomas SchallThomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping…